Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Interleukin-1RACP / Interleukin-1R3 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:IL-1RAcP, IL-1R3, IL-1RAcP / IL-1R3, interleukin 1 receptor accessory protein, IL-1 receptor accessory protein
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RD191518200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

5 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

100 – 3 200 pg/ml

Limit of Detection

16 pg/ml

Intra-assay (Within-Run)

n = 8, CV = 2.5%

Inter-assay (Run-to-Run)

n = 6, CV = 5.6%

Spiking Recovery

101.7%

Dilutation Linearity

98.1%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures IL-1RAcP in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation, Immune Response, Infection and Inflammation, Oncology, Reproduction

Summary

Interleukin 1 (IL-1) induces synthesis of acute phase and proinflammatory proteins during infection, tissue damage, or stress, by forming a complex with interleukin 1 receptor (Il-1R) and its accessory protein. The interleukin 1 receptor accessory protein (IL-1RAcP / IL-1R3) is a necessary part of the IL-1 / IL-1R complex, which initiates signalling events that result in the activation of inflammatory response.
Due to its role in mechanism of regulation of interleukin 1 responsiveness, IL-1RAcP has been suggested to be involved in various pathological states in organism.
Plasma IL-1RAcP levels are reduced in obesity, thus, plasma IL-1RacP can potentially serve as a biomarker of obesity. Blood IL-1RAcP levels are consistently low throughout the menstrual cycle of women with endometriosis, which is one of the most frequent gynecological diseases in women of reproductive age. Lower circulating levels of IL-1RAcP point to a significant impairment in the regulatory mechanisms of IL-1, which, in view of the cytokine´s crucial role in inflammation, may play a role in pathophysiology of endometriosis.
Acute Myeloid leukemia (AML) is a hematologic malignancy with poor survival. Current treatment with chemotherapy does not target the leukemic cells specifically and is associated with severe side effects. Studies indicate, that antibodies directed to the IL-1RAcP molecule expressed on immature AML cells show strong antileukemic effects in mice transplanted with human AML cells. These studies on animal models provide evidence in support of rapid clinical development of an antibody based anti-IL-1RAcP therapy in AML.
Recently, interleukin-1ß and interleukin-1 receptor accessory protein gene polymorphisms were associated with persistent hepatitis B virus infection (chronic hepatitis, liver cirrhosis) and hepatocellular carcinoma.

References to Summary

References to Interleukin-1 receptor accessory protein

  • Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S2, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T: Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci U S A, 2015;112(34):10786-91
  • Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR Jr, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ: GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015;138:3076-88
  • Bozaoglu K, Attard C, Kulkarni H, Cummings N, Diego VP, Carless MA, Shields KA, Johnson MP, Kowlessur S, Dyer TD, Comuzzie AG, Almasy L, Zimmet P, Moses EK, Göring HH, Curran JE, Blangero J, Jowett JB: Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity. Clin Endocrinol Metab 2014;99(9):3435-43
  • Michaud N, Al-Akoum M, Akoum A1: Blood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis. Reprod Biol Endocrinol 2014;12:51
  • Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L Fernandez HF, Greenberg PL, Tallman MS, Steidl Ch, Mitsiades CS, Verma A and Steidlcorresponding U: Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012; 120(6): 1290–1298.
  • Kim SS, Cheong JY, Lee D, Lee SK, Kim MH, Kwack K, Yang SJ, Lee HY, Cho SW: Interleukin-1ß and interleukin-1 receptor accessory protein gene polymorphisms are associated with persistent hepatitis B virus infection. Hepatogastroenterology 2012; 59(113):190-7
  • Jensen LE, Muzio M, Mantovani A, Whitehead AS: IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 2000;164(10):5277-86
  • Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, Chizzonite RA, Labow MA: IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161(10):5614-20
  • Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU: The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998;161(12):6871-7
Related Products Documents